Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
Identifieur interne : 000349 ( Main/Exploration ); précédent : 000348; suivant : 000350Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
Auteurs : Robert A. Hauser [États-Unis] ; Aaron L. Ellenbogen [États-Unis] ; Leo Verhagen Metman [États-Unis] ; Ann Hsu [États-Unis] ; Martin J. O'Connell [États-Unis] ; Nishit B. Modi [États-Unis] ; Hsuan-Ming Yao [États-Unis] ; Sherron H. Kell [États-Unis] ; Suneel K. Gupta [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-10.
English descriptors
- KwdEn :
Abstract
The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended‐release formulation of carbidopa‐levodopa, with an immediate‐release carbidopa‐levodopa formulation in advanced Parkinson's disease. We performed an open‐label crossover study in 27 subjects with advanced Parkinson's disease experiencing motor fluctuations on levodopa therapy. Subjects were randomized 1:1 to 8 days' treatment with either immediate‐release carbidopa‐levodopa followed by IPX066 or IPX066 followed by immediate‐release carbidopa‐levodopa. Pharmacokinetic and motor assessments were undertaken on day 1 for 8 hours (following a single dose) and on day 8 for 12 hours (during multiple‐dose administration). Following a single dose of IPX066 or immediate‐release carbidopa‐levodopa, plasma levodopa concentrations increased at a similarly rapid rate and were sustained above 50% of peak concentration for 4 hours with IPX066 versus 1.4 hours with immediate‐release carbidopa‐levodopa (P < .0001). Multiple‐dose data showed IPX066 substantially reduced variability in plasma levodopa concentrations despite a lower dosing frequency (mean, 3.5 vs 5.4 administrations per day). In addition, total levodopa exposure during IPX066 treatment was approximately 87% higher, whereas the increase in levodopa Cmax was approximately 30% compared with immediate‐release carbidopa‐levodopa. Both products were well tolerated. IPX066 provided more sustained plasma levodopa concentrations than immediate‐release carbidopa‐levodopa. Larger, longer‐term, well‐controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23861
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Ellenbogen, Aaron L" sort="Ellenbogen, Aaron L" uniqKey="Ellenbogen A" first="Aaron L." last="Ellenbogen">Aaron L. Ellenbogen</name></author><author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name></author><author><name sortKey="Hsu, Ann" sort="Hsu, Ann" uniqKey="Hsu A" first="Ann" last="Hsu">Ann Hsu</name></author><author><name sortKey="O Connell, Martin J" sort="O Connell, Martin J" uniqKey="O Connell M" first="Martin J." last="O'Connell">Martin J. O'Connell</name></author><author><name sortKey="Modi, Nishit B" sort="Modi, Nishit B" uniqKey="Modi N" first="Nishit B." last="Modi">Nishit B. Modi</name></author><author><name sortKey="Yao, Hsuan Ing" sort="Yao, Hsuan Ing" uniqKey="Yao H" first="Hsuan-Ming" last="Yao">Hsuan-Ming Yao</name></author><author><name sortKey="Kell, Sherron H" sort="Kell, Sherron H" uniqKey="Kell S" first="Sherron H." last="Kell">Sherron H. Kell</name></author><author><name sortKey="Gupta, Suneel K" sort="Gupta, Suneel K" uniqKey="Gupta S" first="Suneel K." last="Gupta">Suneel K. Gupta</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EFDD9E2393D829514DF101840BC3990DE713A5DF</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/mds.23861</idno><idno type="url">https://api.istex.fr/document/EFDD9E2393D829514DF101840BC3990DE713A5DF/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002163</idno><idno type="wicri:Area/Main/Curation">001E55</idno><idno type="wicri:Area/Main/Exploration">000349</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease</title><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorders Center, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Ellenbogen, Aaron L" sort="Ellenbogen, Aaron L" uniqKey="Ellenbogen A" first="Aaron L." last="Ellenbogen">Aaron L. Ellenbogen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Michigan Institute for Neurological Disorders and Quest Research Institute, Farmington Hills, Michigan</wicri:regionArea><placeName><region type="state">Michigan</region></placeName></affiliation></author><author><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Rush University Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Hsu, Ann" sort="Hsu, Ann" uniqKey="Hsu A" first="Ann" last="Hsu">Ann Hsu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Impax Pharmaceuticals, Hayward, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="O Connell, Martin J" sort="O Connell, Martin J" uniqKey="O Connell M" first="Martin J." last="O'Connell">Martin J. O'Connell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Impax Pharmaceuticals, Hayward, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Modi, Nishit B" sort="Modi, Nishit B" uniqKey="Modi N" first="Nishit B." last="Modi">Nishit B. Modi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Impax Pharmaceuticals, Hayward, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Yao, Hsuan Ing" sort="Yao, Hsuan Ing" uniqKey="Yao H" first="Hsuan-Ming" last="Yao">Hsuan-Ming Yao</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Impax Pharmaceuticals, Hayward, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Kell, Sherron H" sort="Kell, Sherron H" uniqKey="Kell S" first="Sherron H." last="Kell">Sherron H. Kell</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Impax Pharmaceuticals, Hayward, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Gupta, Suneel K" sort="Gupta, Suneel K" uniqKey="Gupta S" first="Suneel K." last="Gupta">Suneel K. Gupta</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Impax Pharmaceuticals, Hayward, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-10">2011-10</date><biblScope unit="volume">26</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="2246">2246</biblScope><biblScope unit="page" to="2252">2252</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">EFDD9E2393D829514DF101840BC3990DE713A5DF</idno><idno type="DOI">10.1002/mds.23861</idno><idno type="ArticleID">MDS23861</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>IPX066</term><term>Parkinson's disease</term><term>extended‐release levodopa</term><term>motor effects</term><term>motor fluctuations</term><term>pharmacokinetics</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of the study was to compare the pharmacokinetics, motor effects, and safety of IPX066, a novel extended‐release formulation of carbidopa‐levodopa, with an immediate‐release carbidopa‐levodopa formulation in advanced Parkinson's disease. We performed an open‐label crossover study in 27 subjects with advanced Parkinson's disease experiencing motor fluctuations on levodopa therapy. Subjects were randomized 1:1 to 8 days' treatment with either immediate‐release carbidopa‐levodopa followed by IPX066 or IPX066 followed by immediate‐release carbidopa‐levodopa. Pharmacokinetic and motor assessments were undertaken on day 1 for 8 hours (following a single dose) and on day 8 for 12 hours (during multiple‐dose administration). Following a single dose of IPX066 or immediate‐release carbidopa‐levodopa, plasma levodopa concentrations increased at a similarly rapid rate and were sustained above 50% of peak concentration for 4 hours with IPX066 versus 1.4 hours with immediate‐release carbidopa‐levodopa (P < .0001). Multiple‐dose data showed IPX066 substantially reduced variability in plasma levodopa concentrations despite a lower dosing frequency (mean, 3.5 vs 5.4 administrations per day). In addition, total levodopa exposure during IPX066 treatment was approximately 87% higher, whereas the increase in levodopa Cmax was approximately 30% compared with immediate‐release carbidopa‐levodopa. Both products were well tolerated. IPX066 provided more sustained plasma levodopa concentrations than immediate‐release carbidopa‐levodopa. Larger, longer‐term, well‐controlled studies should be conducted to provide rigorous assessment of the clinical effects of IPX066. © 2011 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Floride</li><li>Illinois</li><li>Michigan</li></region><settlement><li>Tampa</li></settlement><orgName><li>Université de Floride du Sud</li></orgName></list><tree><country name="États-Unis"><region name="Floride"><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></region><name sortKey="Ellenbogen, Aaron L" sort="Ellenbogen, Aaron L" uniqKey="Ellenbogen A" first="Aaron L." last="Ellenbogen">Aaron L. Ellenbogen</name><name sortKey="Gupta, Suneel K" sort="Gupta, Suneel K" uniqKey="Gupta S" first="Suneel K." last="Gupta">Suneel K. Gupta</name><name sortKey="Hsu, Ann" sort="Hsu, Ann" uniqKey="Hsu A" first="Ann" last="Hsu">Ann Hsu</name><name sortKey="Kell, Sherron H" sort="Kell, Sherron H" uniqKey="Kell S" first="Sherron H." last="Kell">Sherron H. Kell</name><name sortKey="Metman, Leo Verhagen" sort="Metman, Leo Verhagen" uniqKey="Metman L" first="Leo Verhagen" last="Metman">Leo Verhagen Metman</name><name sortKey="Modi, Nishit B" sort="Modi, Nishit B" uniqKey="Modi N" first="Nishit B." last="Modi">Nishit B. Modi</name><name sortKey="O Connell, Martin J" sort="O Connell, Martin J" uniqKey="O Connell M" first="Martin J." last="O'Connell">Martin J. O'Connell</name><name sortKey="Yao, Hsuan Ing" sort="Yao, Hsuan Ing" uniqKey="Yao H" first="Hsuan-Ming" last="Yao">Hsuan-Ming Yao</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000349 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000349 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EFDD9E2393D829514DF101840BC3990DE713A5DF
|texte= Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |